Aastrom Biosciences, Inc. (ASTM), a regenerative medicine company, said Wednesday that it has appointed Daniel Orlando to a newly created position of chief commercial officer.
Most recently, Dan was with Takeda Pharmaceuticals for over 13 years in executive leadership positions in marketing, sales and business development, most recently as vice president, business development for North and South America.
Previously, he was with Abbott Laboratories (ABT) for more than 11 years in progressive sales and marketing roles.
Aastrom Biosciences develops cell therapies for use in the treatment of chronic ischemic cardiovascular diseases.
Aastrom Biosciences shares are currently trading at $1.70, up 2 cents.
For comments and feedback: editorial@rttnews.com